Active surveillance for low-risk prostate cancer

F1000 Medicine Reports

Volumn 4, Issue 1, 2012, Pages

  Klotz, Laurence ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACINAR CELL; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CELL PROLIFERATION; DISEASE COURSE; FOLLOW UP; HUMAN; LOW RISK POPULATION; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE;

EID: 84864928008     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M4-16     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. F1000 Factor 6 Laurence Klotz 23 Jul 2012
2. Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 2010, 102:605-13. F1000 Factor 9 Iris Zalaudek and Aimilios Lallas 22 Sep 2011, Laurence Klotz 23 Jul 2012
3. Wever EM, Draisma G, Heijnsdijk EAM, de Koning HJ: How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Making 2011, 31:550-8. F1000 Factor 6 Laurence Klotz 23 Jul 2012
4. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-8. F1000 Factor 15 Karl-Dietrich Sievert 17 Apr 2009, Andreas Skolarikos and Grigoris Athanasiadis 01 May 2009, Cornelis Biesheuvel 07 May 2009, William Dale and Saleha Sajid 24 Feb 2010, Laurence Klotz 23 Jul 2012
5. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl C, Stranne J, Holmberg E, Lilja H: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-32. F1000 Factor 11 James Catto and Kate Linton 06 Jul 2010, Guido Barbagli and Massimo Lazzeri 09 Nov 2010, Laurence Klotz 23 Jul 2012
6. Crawford ED, Grubb R, Black A, Andriole GL, Chen M, Izmirlian G, Berg CD, D'Amico AV: Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011, 29:355-61. F1000 Factor 9 James Catto and Kate Linton 17 Feb 2011, Laurence Klotz 23 Jul 2012
7. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force [http://www.uspreventiveservicestaskforce. org/uspstf12/prostate/prostateart.htm]
8. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson S, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami H, Johansson J: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-17. F1000 Factor 14 Thomas Flaig 24 May 2011, Hendrik van Poppel and Yuri Tolkach 26 Apr 2012, Laurence Klotz 23 Jul 2012
9. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR: Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011, 29:2795-800. F1000 Factor 6 Laurence Klotz 23 Jul 2012
10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995, 154:131-8. F1000 Factor 6 Laurence Klotz 23 Jul 2012
11. Epstein JI: Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 2011, 186:790-7. F1000 Factor 6 Laurence Klotz 23 Jul 2012
12. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71:933-8. F1000 Factor 6 Laurence Klotz 23 Jul 2012
13. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, van Leenders GJLH, Schröder FH, van der Kwast TH: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011, 185:121-5. F1000 Factor 6 Laurence Klotz 23 Jul 2012
14. Klotz L, Thompson I: Early prostate cancer-treat or watch? N Engl J Med 2011, 365:569.
15. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-31.
16. van den Bergh RCN, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009, 55:1-8. F1000 Factor 6 Laurence Klotz 23 Jul 2012
17. Dall ' Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112:2664-70.
18. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, Fujimoto H, Niwakawa M: Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008, 38:122-8. (Pubitemid 351337956)
19. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007, 178:2359-64; discussion; 2364-5. F1000 Factor 6 Laurence Klotz 23 Jul 2012
20. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJLH, Schröder FH: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007, 51:1244-50; discussion 1251. F1000 Factor 6 Laurence Klotz 23 Jul 2012
21. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M: Careful selection and close monitoring of lowrisk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010, 58:831-5. F1000 Factor 9 Alexander Bachmann and Matthias Walter 01 Mar 2011, Laurence Klotz 23 Jul 2012
22. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D: Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005, 95:956-60. (Pubitemid 40655686)
23. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004, 171:1520-4. (Pubitemid 38365409)
24. Krakowsky Y, Loblaw A, Klotz L: Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010, 184:131-5.
25. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010, 28:2810-6. F1000 Factor 8 Robert Huddart 01 Jul 2010, Michael Glode and Thomas Flaig 13 Jul 2010, Laurence Klotz 23 Jul 2012
26. Vickers AJ, Savage C, O'Brien MF, Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403. F1000 Factor 9 George Thalmann 18 Jun 2009, Laurence Klotz 23 Jul 2012
27. Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, Klotz L: Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol 2010, 184:1942-6.
28. Villeirs GM, de Meerleer GO, de Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W: Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a singleinstitution experience of 356 patients. Eur J Radiol 2011, 77:340-5.
29. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M, Peyromaure M, Cornud F: Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011, 14:232-7. F1000 Factor 6 Laurence Klotz 23 Jul 2012
30. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-24. F1000 Factor 6 Laurence Klotz 23 Jul 2012
31. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-202. F1000 Factor 15 John Amory 12 Apr 2010, James Catto and Kate Linton 26 Apr 2010, Benjamin Davies and Jeffrey Tomaszewski 27 Apr 2010, Jaspreet Sandhu 25 May 2010, Jean Pierre Droz and Helen Boyle 25 Jun 2010, Laurence Klotz 23 Jul 2012
32. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebocontrolled trial. Lancet 2012, 379:1103-11. F1000 Factor 19 James Catto and Kate Linton 20 Feb 2012, Thomas Flaig 22 Feb 2012, Robert Huddart 16 Mar 2012, Yoshihiko Hirao and Kiyohide Fujimoto 29 Mar 2012, Hendrik van Poppel and Yuri Tolkach 05 Jul 2012, Laurence Klotz 23 Jul 2012
33. Johansson E, Steineck G, Holmberg L, Johansson J, Nyberg T, Ruutu M, Bill-Axelson A: Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011, 12:891-9. F1000 Factor 9 James Catto and Kate Linton 26 Sep 2011, Laurence Klotz 23 Jul 2012
34. Vasarainen H, Lokman U, Ruutu M, Taari K, Rannikko A: Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU Int 2012, 109:1614-9. F1000 Factor 6 Laurence Klotz 23 Jul 2012
35. Kasperzyk JL, Shappley WV, Kenfield SA, Mucci LA, Kurth T, Ma J, Stampfer MJ, Sanda MG: Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol 2011, 186:1862-7.
36. NIH State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer [http:// consensus.nih.gov/ 2011/prostate.htm]